Norway· NO-ID_AE750907-6A60-40E4-94C5-D799B625388D
Orserdu
A elacestrant product containing elacestrant, registered in Norway by Stemline. The same ATC class is registered in 14 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Elacestrant is registered in 14 of 19 countries.
Countries holding a registration under ATC L02BA04 (elacestrant), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 10 of them publish a price we can compare per daily dose
Elacestrant · ATC L02BA04
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of elacestrant costs, country by country.
Normalised to the WHO defined daily dose (0.345 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Elacestrant · price per daily dose (0.345 g)
USD · FX 28 Sept 2026
- CH Switzerland$374.12
The record
At a glance
FEST (Norway)- Active substance
- Elacestrant
- Manufacturer
- Stemline
- Country
- Norway (NO)
- ATC code
- L02BA04
- ATC class
- Elacestrant
- Defined daily dose
- 0.345 g, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 2
- no_merkevare_idID_AE750907-6A60-40E4-94C5-D799B625388D
- no_varenummer34694728
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Elacestrant in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomKorserdu 345mg tabletsMenarini Stemline UK Ltd
- United StatesORSERDUStemline Therapeutics, Inc.
- SwitzerlandOrserdu 345 mg, FilmtablettenStemline Therapeutics Switzerland GmbH
- CzechiaORSERDUStemline Therapeutics B.V., Amsterdam
- SpainORSERDU 345 MG COMPRIMIDOS RECUBIERTOS CON PELICULAStemline Therapeutics B.V.
- FinlandORSERDUStemline Therapeutics B.V.
- FranceORSERDU 345 mg, comprimé pelliculéSTEMLINE THERAPEUTICS (PAYS-BAS)
- BelgiumOrserdu 345 mgStemline Therapeutics
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Orserdu
- Liechtenstein · Orserdu
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cebb0afb-00b6-4d8b-bd70-ae90a3517c33 GET /v1/drugs/cebb0afb-00b6-4d8b-bd70-ae90a3517c33?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablett",
"source": "fest",
"status": "A",
"atc_name": "Elacestrant",
"merkevare_id": "ID_AE750907-6A60-40E4-94C5-D799B625388D",
"name_form_strength": "Orserdu tab 345 mg",
"prescription_group": "C"
}See everything about elacestrant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.